However, most of these treatments have disappointingly been found to be ineffective during the acute phase of stroke, and intravenous recombinant tissue plasminogen activator (r-tPA) is currently the only approved agent for the treatment of acute ischemia stroke [9], and it has safety concerns associated with reperfusion injury and hemorrhage. The gene discussed is PLAT; the disease is stroke disorder.